How big is the diabetic retinopathy market today, and what are its future growth expectations?
The diabetic retinopathy market size has grown strongly in recent years. It will grow from $8.61 billion in 2024 to $9.29 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to aging population, increasing prevalence of diabetes, growing awareness about diabetic retinopathy, improved healthcare infrastructure, rising healthcare expenditure
The diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $12.56 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to personalized medicine approaches, expansion of telemedicine services, development of novel therapeutic interventions, adoption of point-of-care testing, remote patient monitoring. Major trends in the forecast period include precision medicine in diabetic retinopathy treatment, increased focus on early detection and prevention, teleophthalmology services growth, rise in gene therapy research, continuous advancements in retinal imaging technology.
Get Your Free Sample of The Global Diabetic Retinopathy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12187&type=smp
What have been the primary factors driving the diabetic retinopathy market’s growth?
The rising prevalence of diabetes is expected to propel the growth of the diabetic retinopathy market going forward. Diabetes refers to a long-term metabolic disease that causes high blood glucose levels. The rise in the prevalence of diabetes is mainly driven by overweight, obesity, genetics, and physical inactivity, whereas patients with diabetes have too much sugar in their blood, which can damage the retina, which is part of the eye that detects light and sends signals to your brain through a nerve in the back of eye. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, it rose by 21%. The proportion of people meeting target HbA1c levels also reached 37.9%, the highest ever recorded by the National Diabetes Audit. Therefore, the rising prevalence of diabetes is driving the growth of the diabetic retinopathy market.
What are the key segments within the diabetic retinopathy market?
The diabetic retinopathy market covered in this report is segmented –
1) By Type: Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy
2) By Treatment: Anti-VEGF Drugs, Intraocular Steroid Injection, Laser Photocoagulation, Vitreoretinal Surgery
3) By End-User: Hospitals, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Proliferative Diabetic Retinopathy (PDR): Neovascularization, Vitreous Hemorrhage, Tractional Retinal Detachment
2) By Non-Proliferative Diabetic Retinopathy (NPDR): Mild NPDR, Moderate NPDR, Severe NPDR
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report
Which key players are shaping the diabetic retinopathy market?
Major companies operating in the diabetic retinopathy market include Pfizer Inc., F-Hoffmann-La Roche Ltd., Abbvie Inc., Bayer AG, Novartis AG, Ellex Medical Lasers Ltd., Abbott Laboratories Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Icon Bioscience Inc., Allergan plc., Genentech Inc., Aurobindo Pharma, Santen Pharmaceutical Co. Ltd., Carl Zeiss Meditec AG, Valeant Pharmaceuticals International Inc., Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co. Ltd., IRIDEX Corporation, Alimera Science Inc., Kowa Company Ltd., Ocular Therapeutix Inc., Aerpio Pharmaceuticals Inc., Kodiak Sciences Inc., Oxurion NV, Graybug Vision Inc., Ampio Pharmaceuticals Inc.
How will emerging trends drive the diabetic retinopathy market throughout the forecast period?
Technological advancements are a key trend gaining popularity in the diabetic retinopathy market. Major companies operating in the large volume parenteral market are adopting new technologies to sustain their position in the market. For instance, in July 2022, Baxter International Inc., a US-based healthcare company, launched Welch Allyn RetinaVue 100 Imager PRO in South Korea. These technologies are intended to allow for the detection of diabetic retinopathy in primary care settings. RetinaVue has proven to increase patient compliance for potentially life-saving annual diabetic retinal exams (DREs) by screening patients quickly and comfortably during a routine primary care visit.
How do regional factors impact the diabetic retinopathy market, and which region is the largest contributor?
North America was the largest region in the diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Diabetic Retinopathy Market Report 2025 Offer?
The diabetic retinopathy market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Diabetic retinopathy is a complication of diabetes that affects the retina, the light-sensitive tissue at the back of the eye, resulting from damage to blood vessels caused by prolonged high blood sugar levels; this condition can lead to vision loss and even blindness if not properly managed, making regular eye examinations essential for early detection and treatment.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12187
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
